The Tumor Microenvironment and Inflammation Influence toxicity in patients with Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel [Nanostring]

Tumor biopsies were taken within one month prior to CAR T infusion for evaluation of gene expression. Baseline tumor gene expression was compared between patients who went on to have severe (grade 3 or higher) neurotoxicity vs. those with non-severe neurotoxicity (grade 0 - 2). Tumor biopsies were taken within one month of CAR T infusion in a cohort of 36 patients. RNA expression was measured by the Nanostring IO360 panel consisting of 770 genes found in the tumor microenviroment in cancer. We compared gene expression of the pre-treatment biopsy samples of patients who developed severe immune mediated toxicities ( Grade > 3 neurotoxicity) vs. those with grade 0-2 toxcities after CAR T infusion. We compared patients who went on to have a durable response (DR) to those with a non-durable response (NDR) in patients that had sufficient follow up (minimum 6 months post-CAR T infusion).

本研究于嵌合抗原受体T细胞（CAR-T）输注前1个月内采集肿瘤活检样本，用于基因表达评估。针对后续发生重度（3级及以上）神经毒性的患者与轻度（0~2级）神经毒性的患者，对比其基线肿瘤基因表达水平。本队列共纳入36例患者，于CAR-T输注后1个月内采集肿瘤活检样本。采用Nanostring IO360检测面板（Nanostring IO360 panel）对RNA表达水平进行检测，该面板涵盖癌症肿瘤微环境中的770个基因。我们对CAR-T输注后出现重度免疫介导毒性（3级以上神经毒性）的患者与出现0~2级毒性的患者的治疗前活检样本的基因表达水平开展对比分析。在随访时长充足（CAR-T输注后至少随访6个月）的患者中，将后续获得持续缓解（Durable Response, DR）的患者与非持续缓解（Non-Durable Response, NDR）患者进行对比分析。